MCID: RCT020
MIFTS: 39

Rectum Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Rectum Adenocarcinoma

MalaCards integrated aliases for Rectum Adenocarcinoma:

Name: Rectum Adenocarcinoma 12 15
Rectal Adenocarcinoma 12 6 17
Adenocarcinoma of Rectum 72

Classifications:



External Ids:

Disease Ontology 12 DOID:1996
NCIt 50 C9383
UMLS 72 C0149978

Summaries for Rectum Adenocarcinoma

Disease Ontology : 12 A rectum cancer that derives from epithelial cells of glandular origin.

MalaCards based summary : Rectum Adenocarcinoma, also known as rectal adenocarcinoma, is related to mammary paget's disease and anal canal adenocarcinoma. An important gene associated with Rectum Adenocarcinoma is RAB11B (RAB11B, Member RAS Oncogene Family), and among its related pathways/superpathways is Cytoskeletal Signaling. The drugs Trioxsalen and Tegafur have been mentioned in the context of this disorder. Affiliated tissues include lymph node, colon and liver.

Related Diseases for Rectum Adenocarcinoma

Diseases related to Rectum Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
# Related Disease Score Top Affiliating Genes
1 mammary paget's disease 30.8 KRT7 KRT20
2 anal canal adenocarcinoma 30.8 KRT7 CDX2
3 appendix adenocarcinoma 30.7 KRT7 KRT20 CDX2
4 mucinous adenocarcinoma 30.7 KRT7 KRT20 CDX2
5 cystadenoma 30.7 KRT7 KRT20
6 colorectal adenocarcinoma 30.6 KRT7 KRT20 CEACAM5 CDX2
7 large intestine adenocarcinoma 30.6 KRT7 KRT20
8 anus cancer 30.3 KRT7 DCXR CDX2
9 cystic teratoma 30.3 KRT7 KRT20 CDX2
10 signet ring cell adenocarcinoma 30.3 KRT7 KRT20 CDX2
11 tubular adenocarcinoma 30.2 KRT20 CDX2
12 intrahepatic cholangiocarcinoma 30.2 KRT7 KRT20 CDX2
13 papillary adenocarcinoma 30.1 KRT7 CEACAM5
14 cholangiocarcinoma 29.7 KRT7 KRT20 CEACAM5 CDX2
15 gastric adenocarcinoma 29.6 KRT7 KRT20 CEACAM5 CDX2
16 lung cancer susceptibility 3 29.6 KRT7 KRT20 CEACAM5 CDX2
17 large intestine cancer 26.8 RAB1A RAB11B KRT7 KRT20 DKKL1 DCXR
18 rectum mucinous adenocarcinoma 11.3
19 ovary neuroendocrine neoplasm 10.7 KRT7 CDX2
20 cecal benign neoplasm 10.7 RAB11B KRT7
21 cystic basal cell carcinoma 10.7 KRT7 KRT20
22 epithelial predominant wilms' tumor 10.7 KRT7 CDX2
23 malignant syringoma 10.7 KRT7 KRT20
24 duodenum adenocarcinoma 10.7 KRT7 CDX2
25 transverse colon cancer 10.7 KRT7 KRT20
26 seminal vesicle adenocarcinoma 10.7 KRT7 KRT20
27 krukenberg carcinoma 10.6 KRT7 KRT20
28 eyelid carcinoma 10.6 KRT7 KRT20
29 papillary transitional carcinoma 10.6 KRT7 KRT20
30 small cell carcinoma of the bladder 10.6 KRT7 KRT20
31 nasal cavity cancer 10.6 KRT7 CDX2
32 lung acinar adenocarcinoma 10.6 KRT7 KRT20
33 linitis plastica 10.6 KRT7 KRT20
34 nasal cavity adenocarcinoma 10.6 KRT7 CDX2
35 vaginal tubulovillous adenoma 10.6 KRT20 CDX2
36 villous adenoma 10.6 KRT20 CDX2
37 vaginal adenoma 10.6 KRT20 CDX2
38 intratubular embryonal carcinoma 10.6 KRT7 KRT20
39 vaginal benign neoplasm 10.6 KRT20 CDX2
40 adenoid squamous cell carcinoma 10.6 KRT7 KRT20
41 bile duct adenoma 10.6 KRT7 KRT20
42 papillary serous adenocarcinoma 10.6 KRT7 KRT20
43 bladder lymphoma 10.6 KRT7 KRT20
44 glycogen-rich clear cell breast carcinoma 10.6 KRT7 KRT20
45 anal gland adenocarcinoma 10.6 KRT7 CEACAM5
46 cutaneous mucoepidermoid carcinoma 10.6 KRT7 CEACAM5
47 medulloepithelioma 10.6 KRT7 KRT20
48 malignant spiradenoma 10.6 KRT7 CEACAM5
49 renal pelvis carcinoma 10.6 KRT7 KRT20
50 anal paget's disease 10.6 CEACAM5 CDX2

Graphical network of the top 20 diseases related to Rectum Adenocarcinoma:



Diseases related to Rectum Adenocarcinoma

Symptoms & Phenotypes for Rectum Adenocarcinoma

Drugs & Therapeutics for Rectum Adenocarcinoma

Drugs for Rectum Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trioxsalen Approved Phase 2, Phase 3 3902-71-4 5585
2
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
3 Anesthetics Phase 3
4 Antibodies Phase 3
5 Immunoglobulins Phase 3
6 Cola Phase 3
7 Dihematoporphyrin Ether Phase 2, Phase 3
8 Hematoporphyrin Derivative Phase 2, Phase 3
9
Bevacizumab Approved, Investigational Phase 2 216974-75-3
10
Lenograstim Approved, Investigational Phase 2 135968-09-1
11
Melphalan Approved Phase 2 148-82-3 460612 4053
12
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
13
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
14
Gemcitabine Approved Phase 2 95058-81-4 60750
15
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
16
Pembrolizumab Approved Phase 2 1374853-91-4
17
Simvastatin Approved Phase 2 79902-63-9 54454
18
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
19
Metformin Approved Phase 2 657-24-9 4091 14219
20
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
21
Pancrelipase Approved, Investigational Phase 2 53608-75-6
22
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
23 Bryostatin 1 Investigational Phase 2 83314-01-6
24 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
25
Veliparib Investigational Phase 2 912444-00-9 11960529
26 Fluorodeoxyglucose F18 Phase 2
27 Angiogenesis Inhibitors Phase 2
28 Angiogenesis Modulating Agents Phase 2
29 Antibodies, Monoclonal Phase 2
30 Liver Extracts Phase 2
31 Alkylating Agents Phase 2
32 Antineoplastic Agents, Alkylating Phase 2
33 Immunoglobulin G Phase 2
34 Endothelial Growth Factors Phase 2
35 Folic Acid Antagonists Phase 2
36 Cyclosporins Phase 2
37 Dermatologic Agents Phase 2
38 Calcineurin Inhibitors Phase 2
39 Antirheumatic Agents Phase 2
40 Antifungal Agents Phase 2
41 Nucleic Acid Synthesis Inhibitors Phase 2
42 Anti-Infective Agents Phase 2
43 Antiviral Agents Phase 2
44 Mitogens Phase 2
45 Hormones Phase 2
46 Hematinics Phase 2
47 Bone Density Conservation Agents Phase 2
48 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
49 Lipid Regulating Agents Phase 2
50 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 A Phase III Randomised Study Of J-Pouch Coloanal Anastomosis Versus Side-To-End Coloanal Anastomosis After Preoperative Radiotherapy And Total Mesorectal Excision In Patients With Mid And Distal Rectal Cancer Unknown status NCT00070005 Phase 3
2 Prospective Randomized Clinical Trial for no Inferiority With Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery (TEM) Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer Unknown status NCT01308190 Phase 3 Capecitabine (Xeloda)
3 A Phase III, Randomized Study of Adjuvant Chemotherapy for Patients With Rectal Adenocarcinoma Who Achieved Suboptimal Response After Neoadjuvant Chemo-radiotherapy. Unknown status NCT01941979 Phase 3 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
4 A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT) Unknown status NCT00601549 Phase 3
5 A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum Completed NCT00145769 Phase 3 Short Course Adjuvent Chemotherapy;Long Course Adjuvant Chemotherapy;Concurrent Chemotherapy
6 GRECCAR 8 : Impact on Survival of the Primary Tumor Resection in Rectal Cancer With Unresectable Synchronous Metastasis a Randomized Multicenter Study Completed NCT02314182 Phase 3 Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab
7 Phase II Trial Comparing Two Neoadjuvant Treatments in Patients With Ultra-low Rectal Cancer: High-dose Radiotherapy Versus Radio-chemotherapy Completed NCT00979680 Phase 3
8 Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004. Completed NCT03428529 Phase 2, Phase 3 Capecitabine Oral Product;5Fluorouracil
9 European Phase III Study Comparing a Radiation Dose Escalation Using 2 Different Approaches : External Beam Radiation Therapy Versus Endocavitary Radiation Therapy With Contact X-ray Brachytherapy 50 kiloVolts (kV) for Patients With Rectal Adenocarcinoma Recruiting NCT02505750 Phase 3 Capecitabine
10 A Multicentric Randomised Trial to Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy Versus Standard Transabdominal Laparoscopic Proctectomy for Low Lying Rectal Cancer (ETAP-GRECCAR 11) Recruiting NCT02584985 Phase 3
11 Longterm Outcome of Photodynamic Therapy Compared With Chemotherapy Alone in Patients With Advanced Rectal Cancer Suspended NCT01872104 Phase 2, Phase 3
12 Trial UFT/RT Randomized Multicenter Phase III Randomized Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma Terminated NCT00207831 Phase 3 Tegafur and Uracil
13 Non-Operative Treatment for Rectal Cancer Following Complete Response to Neo-Adjuvant Therapy Unknown status NCT01047969 Phase 2 Adjuvant Chemotherapy
14 Treatment of Induction With XELOX-Bevacizumab in Locally Advanced Rectal Adenocarcinoma: Phase II Study Unknown status NCT00557713 Phase 2 bevacizumab
15 Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis Unknown status NCT01674309 Phase 2 FOLFORINOX
16 Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer Unknown status NCT00075556 Phase 2 capecitabine
17 Efficacy and Safety of Neoadjuvant Chemo-chemoradio-chemo Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer: a Phase II Trial Unknown status NCT02022852 Phase 2 Capecitabine;XELOX
18 Study of the Value of the PET/CT in Evaluating the Response of Distal Rectal Cancer to Neoadjuvant Chemoradiation Therapy Unknown status NCT00254683 Phase 2
19 Open Randomized Study of Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy Unknown status NCT02052921 Phase 2
20 ESTUDIO FASE II DE BEVACIZUMAB EN COMBINACIÓN CON CAPECITABINA Y RADIOTERAPIA COMO TRATAMIENTO PREOPERATORIO EN PACIENTES CON CÁNCER RECTAL LOCALMENTE AVANZADO RESECABLE Completed NCT00847119 Phase 2 capecitabine (Xeloda)
21 Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma Completed NCT01554059 Phase 2 Bevacizumab;Oxaliplatin;5-FU
22 Phase II Trial of Low Dose Whole Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed T3N0M0, T2N1M0, or T3N1M0 Rectal Adenocarcinoma Completed NCT02319304 Phase 2 FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}
23 A Single-Arm Prospective Trial Evaluating The Local And Systemic Benefits Of Oxaliplatin And 5FU With Concurrent Radiation In Patients With Metastatic Rectal Cancer Completed NCT00422864 Phase 2 oxaliplatin;fluorouracil;leucovorin
24 Open-label Phase II Study of Induction Treatment With Folfoxiri Plus Bevacizumab Followed by Preoperative Chemoradiotherapy Plus Bevacizumab in Patients With Locally Advanced, Resectable Rectal Cancer. Completed NCT03085992 Phase 2 FOLFOXIRI plus Bevacizumab
25 Phase II Study of Bryostatin 1 in Patients With Metastatic Colo-Rectal Adenocarcinoma Completed NCT00003220 Phase 2 bryostatin 1
26 Frontline Chemotherapy "Reinforced" for Cancers of the Colon and Rectum With Potentially Resectable Hepatic and/or Pulmonary Metastases: Association of FOLFIRI and ERBITUX Completed NCT00557102 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
27 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
28 Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer Completed NCT00321685 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Oxaliplatin
29 Exploratory Study of Non-Myeloablative Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy Completed NCT00001880 Phase 2 methotrexate;cyclosporin
30 Phase II Study of Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced (T3 and T4 or Node Positive) Rectal Adenocarcinoma Recruiting NCT02919878 Phase 2 Gemcitabine;capecitabine
31 Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER Recruiting NCT02268006 Phase 2 Capecitabine
32 Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma Recruiting NCT02688712 Phase 2 LY2157299;Capecitabine;Fluorouracil
33 Local Excision of Clinical T3 Mid- or Low-Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy: Prospective Multicenter Single-arm Phase II Clinical Trial Recruiting NCT02490709 Phase 2
34 Preoperative Induction Therapy With 12 Weeks of Panitumumab in Combination With mFOLFOX-6 in an Enriched Population (Quadruple Wild-Type) of Patients With mrT3 Rectal Cancer of the Middle Third With Clear Mesorectal Fascia Recruiting NCT03000374 Phase 2 Panitumumab;5Fluorouracil;Oxaliplatin;Leucovorin
35 GI-116: Phase II Study of Organ Preservation in Early Rectal Cancer Patients Recruiting NCT03548961 Phase 2 FOLFOX regimen
36 A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer Recruiting NCT02921256 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Oxaliplatin;Veliparib
37 A Single Arm, Phase II Study of Neoadjuvant Chemoradiotherapy With Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients Active, not recruiting NCT02161822 Phase 2 simvastatin
38 Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma Active, not recruiting NCT03503630 Phase 2 COMPOUND 2055269;mFOLFOX
39 Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas. Terminated NCT01619696 Phase 2
40 A Phase II Study of Capecitabine, Oxaliplatin and Selenomethionine and Radiation Therapy in Patients With Stage II and III Rectal Adenocarcinoma Terminated NCT00625183 Phase 2 capecitabine;oxaliplatin
41 Pilot Study: Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth Terminated NCT01632020 Phase 2 Placebo;Metformin
42 A Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of the Rectum Terminated NCT00580073 Phase 2 FOLFOX4;Cetuximab
43 Phase II Study of Capecitabine, Oxaliplatin and Cetuximab Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma Terminated NCT00353457 Phase 2 Capecitabine, Oxaliplatin and Cetuximab
44 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
45 (Bayer Study ONC-2013-036) A Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients With T3, T4 or Node-Positive Rectal Cancer Patients Who Completed Curative-Intent Treatment Withdrawn NCT02287727 Phase 2 Regorafenib
46 A Phase II Feasibility Translational Research Trial of Induction Chemotherapy Followed by Concomitant Chemoradiation in Patients With Clinical T4 Rectal Cancer Withdrawn NCT00070434 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin;Pyridoxine
47 A Pilot and Phase II Study of Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma Withdrawn NCT01302613 Phase 1, Phase 2 Capecitabine;5-FU;Leucovorin;Oxaliplatin
48 An Investigator Sponsored Phase I Trial of Selinexor Combined With Standard Capecitabine Based Chemoradiation as a Neoadjuvant Treatment in Locally Advanced Rectal Cancer Unknown status NCT02137356 Phase 1 standard dose capecitabine;dose-escalated selinexor treatment
49 A Phase I Study of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Capecitabine and Radiation Therapy for the Treatment of Stage II and III Rectal Adenocarcinoma Completed NCT01634685 Phase 1 Bavituximab;Capecitabine
50 Phase I Study of T Cells Modified With Chimeric AntiCEA Immunoglobulin-T Cell Receptors (IgTCR) in Adenocarcinoma Completed NCT00004178 Phase 1

Search NIH Clinical Center for Rectum Adenocarcinoma

Genetic Tests for Rectum Adenocarcinoma

Anatomical Context for Rectum Adenocarcinoma

MalaCards organs/tissues related to Rectum Adenocarcinoma:

41
Lymph Node, Colon, Liver, Testes, Bone, Endothelial, Prostate

Publications for Rectum Adenocarcinoma

Articles related to Rectum Adenocarcinoma:

(show top 50) (show all 1881)
# Title Authors PMID Year
1
Spontaneous coronary artery dissection during cisplatin and capecitabine therapy. 38
31338186 2019
2
Multimodality Imaging Review of Anorectal and Perirectal Diseases With Histological, Endoscopic, and Operative Correlation, Part I: Anatomy and Neoplasms. 38
30172447 2019
3
Surgical treatment of rectal cancer patients aged 80 years and older-a German nationwide analysis comparing short- and long-term survival after laparoscopic and open tumor resection. 38
31092363 2019
4
Diffusion kurtosis imaging-derived histogram metrics for prediction of KRAS mutation in rectal adenocarcinoma: Preliminary findings. 38
30637861 2019
5
Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer. 38
30963400 2019
6
Impact of residual nodal involvement after complete tumor response in patients undergoing neoadjuvant (chemo)radiotherapy for rectal cancer. 38
31378480 2019
7
Rectal adenocarcinoma coexisting with incidentally found microscopic gastrointestinal stromal tumor: A case report. 38
31374035 2019
8
Clinical outcomes of preoperative chemoradiotherapy in octogenarian with locally advanced rectal cancer. 38
31281654 2019
9
Dissection of the inferior mesenteric vein versus of the inferior mesenteric artery for the genitourinary function after laparoscopic approach of rectal cancer surgery: a randomized controlled trial. 38
31382934 2019
10
Robotic proctectomy for rectal cancer in the US: a skewed population. 38
31372887 2019
11
CT Staging to Triage Selection of Patients With Poor-Prognosis Rectal Cancer for Neoadjuvant Treatment. 38
30995084 2019
12
MRI radiomics analysis for predicting preoperative synchronous distant metastasis in patients with rectal cancer. 38
30413955 2019
13
O6-methylguanine-DNA Methyltransferase Promoter Methylation in Patients with Rectal Adenocarcinoma After Chemoradiotherapy Treatment: Clinical Implications 38
31199091 2019
14
Transanal endolaparoscopic resection of T2N0M0 low rectal adenocarcinoma followed by adjuvant therapy. 38
31055878 2019
15
Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma. 38
31426827 2019
16
Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma. 38
30696723 2019
17
EUS versus magnetic resonance imaging in staging rectal adenocarcinoma: a diagnostic test accuracy meta-analysis. 38
31004599 2019
18
The Pelvis-First Approach for Robotic Proctectomy in Patients with Redundant Abdominal Colon. 38
31102088 2019
19
An anatomic anal sphincter-saving procedure for rectal cancers located at anorectal junction. 38
31375146 2019
20
Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing. 38
31049795 2019
21
Distinct Prognosis of High Versus Mid/Low Rectal Cancer: a Propensity Score-Matched Cohort Study. 38
30617772 2019
22
Oncological Outcomes of Patients with Locally Advanced Rectal Cancer and Lateral Pelvic Lymph Node Involvement. 38
31012043 2019
23
Determinants of Rectal Cancer Patients' Decisions on Where to Receive Surgery: a Qualitative Analysis. 38
30203231 2019
24
Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer. 38
31025789 2019
25
Radiation Therapy Dose Escalation to Clinically Involved Pelvic Sidewall Lymph Nodes in Locally Advanced Rectal Cancer. 38
31360803 2019
26
Right pelvic kidney during intersphincteric resection for locally advanced rectal cancer: a case report. 38
31288853 2019
27
PET/MRI and PET/CT hybrid imaging of rectal cancer - description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study. 38
31337428 2019
28
Fatal epidural abscess with meningitis: a rare complication of colorectal surgery. 38
31311450 2019
29
Competitive Endogenous RNA (ceRNA) Regulation Network of lncRNA-miRNA-mRNA in Colorectal Carcinogenesis. 38
30734239 2019
30
Long-term outcomes after surgical dissection of inguinal lymph node metastasis from rectal or anal canal adenocarcinoma. 38
31340778 2019
31
Cardiac arrhythmia from epinephrine overdose in epidural test dose. 38
31333374 2019
32
Rectal cancer: can T2WI histogram of the primary tumor help predict the existence of lymph node metastasis? 38
31278581 2019
33
Temporary end-on colostomy as a treatment for anastomotic dehiscence after a transanal rectal pull-through procedure in a dog. 38
30615223 2019
34
Rectal Invasion by Prostatic Adenocarcinoma That Was Initially Diagnosed in a Rectal Polyp on Colonoscopy. 38
30971069 2019
35
Penile metastases of rectal adenocarcinoma after abdominoperineal resection: a case report. 38
31351481 2019
36
Screening key lncRNAs for human rectal adenocarcinoma based on lncRNA-mRNA functional synergistic network. 38
31116002 2019
37
Transanal endoscopic microsurgery for rectal lesions in a specialist regional early rectal cancer centre: the Mersey experience. 38
31207005 2019
38
[Effect of preservation of left colic artery on postoperative anastomotic leakage of patients with rectal cancer after neoadjuvant therapy]. 38
31238636 2019
39
Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection. 38
30904173 2019
40
Combined Proctectomy and Hepatectomy for Metastatic Rectal Cancer Should be Undertaken with Caution: Results of a National Cohort Study. 38
31201596 2019
41
Isolated Vaginal Recurrence of Early-Stage Rectal Cancer Detected by 18F-FDG PET/CT. 38
30985425 2019
42
Intrahepatic adrenocortical adenoma arising from adrenohepatic fusion mimicking hepatic malignancy: Two case reports. 38
31169702 2019
43
Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy. 38
30823845 2019
44
Rab5C enhances resistance to ionizing radiation in rectal cancer. 38
30968159 2019
45
Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. 38
31253631 2019
46
Evaluation of Access to Hospitals Most Ready to Achieve National Accreditation for Rectal Cancer Treatment. 38
30785616 2019
47
Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. 38
30935775 2019
48
Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. 38
30825182 2019
49
Five-year oncological outcomes after selective neoadjuvant radiotherapy for resectable rectal cancer. 38
31237192 2019
50
Impact of enhanced recovery on oncological outcomes following minimally invasive surgery for rectal cancer. 38
30861099 2019

Variations for Rectum Adenocarcinoma

ClinVar genetic disease variations for Rectum Adenocarcinoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC): c.6152A> G (p.Lys2051Arg) single nucleotide variant Uncertain significance rs1554087256 5:112177443-112177443 5:112841746-112841746
2 APC NM_000038.6(APC): c.3160C> T (p.His1054Tyr) single nucleotide variant Uncertain significance rs1195583636 5:112174451-112174451 5:112838754-112838754
3 APC NM_000038.6(APC): c.811A> G (p.Met271Val) single nucleotide variant Uncertain significance rs587781464 5:112137057-112137057 5:112801360-112801360
4 APC NM_000038.6(APC): c.1984C> A (p.Leu662Ile) single nucleotide variant Uncertain significance rs756859993 5:112173275-112173275 5:112837578-112837578

Expression for Rectum Adenocarcinoma

Search GEO for disease gene expression data for Rectum Adenocarcinoma.

Pathways for Rectum Adenocarcinoma

Pathways related to Rectum Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.41 RAB1A RAB11B KRT7 KRT20

GO Terms for Rectum Adenocarcinoma

Biological processes related to Rectum Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 melanosome transport GO:0032402 8.62 RAB1A RAB11B

Sources for Rectum Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....